1-4 of 4
Sharon Dines
Close
Sort by
Journal Articles

Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation

Faith E. Davies, Ping Wu, Kevin Boyd, Radovan Saso, Michael N Potter, Mark E Ethell, Bronwen E Shaw, Jenny Treleaven, Sharon Dines, Gareth J Morgan
Journal: Blood
Blood (2008) 112 (11): 3313.
https://doi.org/10.1182/blood.V112.11.3313.3313
Published: 2008
Journal Articles

Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients.

Mark D. Linch, MD, Matthew W. Jenner, MD, Sharon Dines, Faith E. Davies, MD, Gareth J. Morgan, PhD
Journal: Blood
Blood (2007) 110 (11): 4841.
https://doi.org/10.1182/blood.V110.11.4841.4841
Published: 2007
Journal Articles

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

Gareth J. Morgan, PhD, Stephen Schey, MD, Ping Wu, M. Srikanth, MD, Karen J. Phekoo, Matthew W. Jenner, MD, Sharon Dines, Radovan Saso, MD, Faith E. Davies, MD
Journal: Blood
Blood (2006) 108 (11): 3555.
https://doi.org/10.1182/blood.V108.11.3555.3555
Published: 2006
Journal Articles

The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).

Faith E. Davies, MD, Ping Wu, M. Srikanth, MD, Matthew W. Jenner, MD, Sharon Dines, Radovan Saso, MD, Gareth J. Morgan, PhD
Journal: Blood
Blood (2006) 108 (11): 3537.
https://doi.org/10.1182/blood.V108.11.3537.3537
Published: 2006